News | May 02, 2024
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
